Australia's approach to newborn diagnostic testing seems very confusing. One reason cited in rejecting Pompe was the risk of 'hypervigilant' parents. Pompe is a degenerative condition where early diagnosis and treatment are critical. Yet some state-based research programs are testing for inherited high cholesterol.
Research trials screen babies for hundreds of conditions while existing programs can't all add one
September 30, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
Australia cannot afford complacency on life sciences, AusBiotech warns at 40
October 8, 2026 - - Latest News -
Life sciences sector warns that tax overhaul could push clinical trials offshore
October 8, 2026 - - Latest News -
Moderna and CSIRO launch five year biosecurity collaboration focused on Hendra vaccine
October 8, 2026 - - Latest News
